 The primary end-point of this study is to evaluate the objective response rates, and the secondary end-points are overall survival, progression-free survival and safety profile of low-dose RAD001 everolimus plus cisplatin and HDFL weekly 24-hour infusion of high-dose 5-FU and leucovorin chemotherapy in the first-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer. 